Renaissance Technologies’s Lucid Diagnostics LUCD Stock Holding History

Renaissance Technologies’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-71,300	Closed	-$76.3K	–	3401
2026 Q2	$76.3K	Sell	71,300 -428,361	-86%	-$462K	﹤0.01%	3010
2026 Q1	$575K	Sell	499,661 -326,866	-40%	-$416K	﹤0.01%	2545
2025 Q4	$901K	Buy	826,527 +532,894	+181%	+$596K	﹤0.01%	2338
2025 Q3	$297K	Buy	293,633 +50,354	+21%	+$55K	﹤0.01%	3003
2025 Q2	$280K	Sell	243,279 -215,786	-47%	-$279K	﹤0.01%	3065
2025 Q1	$684K	Buy	+459,065	New	+$551K	﹤0.01%	2611
2022 Q1	–	Sell	-20,000	Closed	-$107K	–	4315
2021 Q4	$107K	Buy	+20,000	New	+$162K	﹤0.01%	3668

Other funds holding LUCD

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Perkins Capital Management Wayzata, Minnesota $140M AUM 109.55% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Renaissance Technologies's LUCD Position: Q3 2026 in Review

Renaissance Technologies sold out of Lucid Diagnostics (LUCD) in Q3 2026, closing a stake of 71,300 shares — an estimated $76.3K sold.

Renaissance Technologies first reported a position in LUCD in Q4 2021 and held it in 7 quarters. The position peaked at $901K in Q4 2025. 82 funds tracked by Wall St. Rank hold LUCD as of Q3 2026.

Renaissance Technologies reported no remaining Lucid Diagnostics position as of Q3 2026 after selling out during the quarter.
Renaissance Technologies sold 71,300 Lucid Diagnostics shares in Q3 2026, an estimated $76.3K.
Renaissance Technologies first reported a position in Lucid Diagnostics in Q4 2021 and held it in 7 quarters.
Renaissance Technologies's Lucid Diagnostics position peaked at $901K in Q4 2025.
82 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.